

## COMPANY OVERVIEW

VistaGen Therapeutics, Inc. (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company committed to developing differentiated new generation medications for central nervous system (CNS) diseases and disorders with high unmet need. Our product candidate portfolio includes three differentiated clinical-stage candidates, PH94B, PH10 and AV-101, which we are developing for multiple CNS indications. Each of VistaGen's drug candidates has a fundamentally different mechanism of action from all currently approved oral drug treatments, and potential for rapid onset therapeutic effects, convenient at-home self-administration, and an exceptional safety profile. We aim to become a fully-integrated biopharmaceutical company that develops and commercializes innovative CNS therapies for large and growing mental health and neurology markets where current treatments are inadequate to meet the needs of millions of patients and caregivers worldwide.

## RECENT NEWS

### VistaGen Therapeutics Announces Common Stock Purchase Agreement for up to \$10.25 Million

Mar 25 2020, 9:00 AM EDT

## STOCK OVERVIEW

Symbol	VTGN
Exchange	Nasdaq
Market Cap	23.13m
Last Price	\$0.4699
52-Week Range	\$0.2943 - \$1.4862

04/08/2020 03:59 PM EDT

## INVESTOR RELATIONS

**VistaGen Therapeutics, Inc.**  
Mark A. McPartland  
Vice President, Corporate Development  
(650) 577-3606  
[markmcp@vistagen.com](mailto:markmcp@vistagen.com)  
  
KCSA Strategic Communications  
Valter Pinto / Allison Soss  
(212) 896-1254 / (212) 896-1267  
[VistaGen@KCSA.com](mailto:VistaGen@KCSA.com)

## MANAGEMENT TEAM

**Shawn K. Singh**  
Chief Executive Officer and Director

**H. Ralph Snodgrass, Ph.D.**  
Founder, President, Chief Scientific Officer and Director

**Mark A. Smith, M.D., Ph.D.**  
Chief Medical Officer

**Jerrold D. Dotson, CPA**  
Vice President, Chief Financial Officer and Secretary

**Mark A. McPartland**  
Vice President of Corporate Development

## VISTAGEN THERAPEUTICS, INC.

343 Allerton Avenue  
South San Francisco, CA 94080

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.